TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-protecting effects into one treatment, potentially revolutionizing acute stroke therapy..

台北和田纳西州查塔努加。，2024年2月2日/PRNewswire/-Lumosa Therapeutics（Lumosa；6535.2）与CHI Memorial一起宣布启动LT3001的2b期临床试验，LT3001是一种治疗急性中风的开创性药物。这种新药将凝块破坏和神经保护作用结合到一种治疗方法中，可能彻底改变急性中风的治疗方法。。

Stroke, a leading cause of adult disability globally, hits particularly hard in Chattanooga, Tenn., an area known as the 'Stroke Belt,' with one of the highest incidences of stroke in the nation. LT3001 aims to extend the critical treatment time window to 24 hours, offering the potential to transform outcomes for countless stroke patients..

中风是全球成人残疾的主要原因，在田纳西州查塔努加（Chattanooga）打击尤为严重，该地区被称为“中风地带”，是全国中风发病率最高的地区之一。LT3001旨在将关键治疗时间窗口延长至24小时，为无数中风患者提供改变预后的潜力。。

Unlike the current U.S. FDA-approved drug, tissue plasminogen activator (t-PA), which must be administered within 4.5 hours after onset of stroke symptoms, Lumosa's LT3001 breaks down clots while also protecting delicate nerve tissues in the brain. This novel approach greatly extends the stroke treatment window to 24 hours, allowing potential treatment for many more stroke victims.  Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment..

与目前美国FDA批准的药物组织型纤溶酶原激活剂（t-PA）不同，组织型纤溶酶原激活剂（t-PA）必须在中风症状发作后4.5小时内给药，Lumosa的LT3001可以分解凝块，同时还能保护大脑中脆弱的神经组织。这种新颖的方法极大地将中风治疗窗口延长到24小时，为更多的中风患者提供了潜在的治疗。Lumosa和CHI Memorial旨在重新定义预防中风残疾和损害的可能性。。

Addressing a Critical Unmet Need

解决关键的未满足需求

CHI Memorial, home to Chattanooga Center for Neurologic Research, LLC (CCNR), serves as the coordinating center for all Lumosa stroke studies in the United States. Thomas Devlin, MD, PhD, who is the medical director of the CHI Memorial Neuroscience Institute, acts as the international principal investigator for both the Lumosa 203 and BRIGHT Phase 2b randomized placebo-controlled, double-blinded trials.  These trials focus on two patient populations: those undergoing mechanical thrombectomy (203 study, NCT05198323) and those who do not (BRIGHT study, NCT05403866).  Both trials address the critical unmet need for more effective stroke treatment..

CHI Memorial是查塔努加神经系统研究中心（CCNR）的所在地，是美国所有羽扇豆中风研究的协调中心。医学博士Thomas Devlin是CHI Memorial Neuroscience Institute的医学主任，他是Lumosa 203和BRIGHT 2b期随机安慰剂对照双盲试验的国际首席研究员。这些试验集中在两个患者群体：接受机械血栓切除术的患者（203研究，NCT05198323）和不接受机械血栓切除术的患者（BRIGHT研究，NCT05403866）。这两项试验都解决了对更有效的中风治疗尚未满足的关键需求。。

With more than 795,000 strokes annually in the U.S., LT3001's 24-hour treatment window could be a game-changer, especially for patients in rural areas and those with limited access to immediate care. One of the only two treatments, the mechanical thrombectomy surgery alone for large vessel occlusion stroke, is effective in less than 50% of patients.  The other one, t-PA, with the strict 4.5-hour time window, limits the treatment to only about 12 percent of stroke victims nationally.  LT3001's combined clot-dissolving and neuroprotective effects offer hope for significantly improved outcomes.

美国每年有795000多例中风，LT3001的24小时治疗窗口可能会改变游戏规则，特别是对于农村地区的患者和获得即时护理的患者。仅有的两种治疗方法之一，仅机械血栓切除术治疗大血管闭塞性卒中，对不到50%的患者有效。另一种是t-PA，它有严格的4.5小时时间窗，将治疗限制在全国范围内只有约12%的中风患者。LT3001的凝块溶解和神经保护作用相结合，为显着改善预后提供了希望。

LT3001 can be administered within 24 hours after stroke onset for smaller, medium, or larger strokes, in both large and smaller rural hospital emergency departments, greatly expanding access and reaching more patients within a broader timeframe..

LT3001可以在中风发作后24小时内用于小型，中型或大型中风，无论是在大型还是小型农村医院急诊科，都可以在更广的时间范围内大大扩大获得途径并惠及更多患者。。

In December 2023, CHI Memorial achieved a significant milestone by enrolling the first U.S. patient in the Lumosa 203, double-blinded stroke study.  Lumosa's 203 and BRIGHT trials are anticipated to be completed in a year or two. For study 203, Lumosa has partnered with 10 medical centers in the U.S., with CHI Memorial being the only one in Tennessee..

2023年12月，CHI Memorial在Lumosa 203双盲中风研究中招募了第一名美国患者，实现了一个重要的里程碑。Lumosa的203和BRIGHT试验预计将在一两年内完成。在203项研究中，卢莫萨与美国10家医疗中心合作，田纳西州只有CHI Memorial一家。。

This groundbreaking initiative aims to redefine stroke treatment possibilities, offering new hope to individuals and families affected by this debilitating condition.  Lumosa and CHI Memorial are committed to advancing medical innovation and improving the lives of stroke patients worldwide.

这项开创性的举措旨在重新定义中风治疗的可能性，为受这种衰弱状况影响的个人和家庭提供新的希望。Lumosa和CHI Memorial致力于推进医学创新，改善全球中风患者的生活。

Contact:Lumosa TherapeuticsTodd Ban[email protected].tw

联系人：Lumosa Therapeutics Todd Ban〔email protected〕.tw

SOURCE Lumosa Therapeutics Co., Ltd.; CHI Memorial

SOURCE Lumosa Therapeutics Co.，Ltd。；池纪念馆